All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000063-10 | A comparison of Metvix PDT with simple excision surgery in subjects with superficial Basal cell Carcinoma (sBCC) | 2006-11-16 | due-trials |
| Reported results | 2004-000700-41 | Comparison of Metvix® PDT with Cryotherapy in Subjects with Actinic Keratoses on locations other than the face and scalp | 2006-02-16 | due-trials |
| Ongoing | 2004-003015-23 | Estudio de la eficacia y seguridad de la Terapia Fotodinámica con Metil Aminolevulinato en crema (Metvix®) en pacientes de alto riesgo con Carcinoma Basocelular Superficial (CBCs). | not-yet-due | |
| Reported results | 2005-005769-12 | FLUORESCENT DETECTION WITH METHYL AMINOLEVULINATE OF BASAL CELL CARCINOMA: TO ASSESS THE ACCURACY OF THIS TECHNIQUE BY COMPARISON WITH RESECTION MARGIN LEFT BY MOH’S MICROGRAPHIC SURGERY AFTER DIFFER... | 2007-03-26 | due-trials |
| Reported results | 2006-000974-54 | A multi-centre, randomized, parallel groups, vehicle and active controlled study of amorolfine 4% and 10% nail lacquer new formulation in the topical treatment of distal and lateral subungual toenail ... | 2008-05-15 | due-trials |
| Reported results | 2006-001999-20 | ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX... | 2007-06-18 | due-trials |
| Reported results | 2006-003073-27 | Subject preference comparison between Clobetasol propionate shampoo, 0.05 and three other topical corticosteroids in the treatment of moderate to severe scalp psoriasis | 2008-01-22 | due-trials |
| Reported results | 2006-003156-37 | AN EXPLORATORY STUDY TO EVALUATE RELAPSES FOLLOWING AN INITIAL 12 WEEKS DOSE-RANGE STUDY WITH CD5024 CREAM VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM IN PAPULO-PUSTULAR ROSACEA – A 6 MONT... | 2007-11-19 | due-trials |
| Reported results | 2006-003707-40 | Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato-telangiectatic rosacea. | 2007-05-23 | due-trials |
| Reported results | 2006-004215-21 | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO DEMONSTRATE THE EFFICACY AND SAFETY OF ADAPALENE/BENZOYL PEROXIDE TOPICAL GEL COMPARED WITH ADAPALENE TOPICAL GEL, 0.1%; BENZOYL PEROX... | 2007-10-05 | due-trials |
| Reported results | 2006-004237-15 | Comparison of Metvix® PDT with its vehicle in the treatment of photoaged skin | 2008-09-01 | due-trials |
| Reported results | 2006-004278-28 | Efficacy and Safety of a Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Compared to Clindamycin 1% / Benzoyl Peroxide 5% Gel in the Treatment of Acne Vulgaris | 2007-10-16 | due-trials |
| Reported results | 2006-006487-32 | CLINICAL EFFICACY EVALUATION OF A FIXED COMBINATION OF CALCITRIOL 3 µg/g WITH THREE CONCENTRATIONS (100, 250, 500µg/g) OF CLOBETASOL PROPIONATE AS SPRAY FORMULATION USING THE MODIFIED DUMAS-SCHOLTZ PS... | 2007-05-14 | due-trials |
| Reported results | 2007-006673-91 | A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CD5024 1% CREAM TREATMENT FOR UP TO 52 WEEKS IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA | 2009-04-17 | due-trials |
| Reported results | 2007-007789-39 | Efficacy and safety comparison of CD4802 0.1% ointment versus vehicle in the treatment of target lesions in adults with atopic dermatitis | 2009-12-03 | due-trials |
| Reported results | 2008-001603-30 | Gene expression in renal transplant patients with field Actinic Keratosis undergoing Metvix® PDT | 2011-10-07 | due-trials |
| Reported results | 2008-002679-29 | Plasma Pharmacokinetics study of CD5024 1% cream in subjects with papulopustular rosacea | 2008-12-01 | due-trials |
| Ongoing | 2008-003854-13 | AN INVESTIGATOR BLIND PARALLEL GROUP VEHICLE CONTROL STUDY COMPARING THE EFFICACY AND SAFETY OF CD 5024 1% CREAM WITH METRONIDAZOLE 0.75% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 16 W... | not-yet-due | |
| Reported results | 2008-005217-22 | Efficacy and Safety of Clobetasol propionate shampoo 0.05% used in association with an antifungal shampoo in the treatment of moderate to severe Scalp Seborrheic Dermatitis | 2010-02-01 | due-trials |
| Reported results | 2008-006792-68 | Efficacy and Safety comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel associated with Lymecycline 300mg Capsules versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Vehicle Gel associated with Lymecy... | 2010-05-01 | due-trials |
| Reported results | 2008-007981-44 | EXPLORATORY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CD5789 IN SUBJECTS WITH ACNE | 2009-03-12 | due-trials |
| Reported results | 2009-010338-23 | Intra-individual randomized comparison of the efficacy of two botulinum toxins type A on moderate to severe forehead wrinkles after one injection | 2010-05-18 | due-trials |
| Reported results | 2009-010498-19 | A MULTICENTER, RANDOMIZED, INTRA-INDIVIDUAL, DOUBLE BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CD2027 OINTMENT 9µG/G APPLIED TWICE DAILY OVER 4 WEEKS IN THE TREATMENT OF TA... | 2009-11-16 | due-trials |
| Reported results | 2009-011212-37 | Anti P. acnes activity of Epiduo® Gel compared to Benzoyl Peroxide 2.5% Gel in the treatment of subjects with acne vulgaris | 2010-08-23 | due-trials |
| Reported results | 2009-013111-35 | EFFECT OF CD08514 VERSUS PLACEBO, IN PATIENTS PRESENTING WITH TYPE 1 ROSACEA, OVER AN 8-WEEK TREATMENT | 2010-06-07 | due-trials |
| Reported results | 2010-018319-13 | A DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE ACTIVITY OF CD5024 1% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 12 WEEKS TREATMENT | 2011-05-02 | due-trials |
| Reported results | 2010-019994-13 | EXPLORATORY STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CD07387 SOLUTION IN PATIENTS WITH VITILIGO | 2011-05-09 | due-trials |
| Reported results | 2010-021936-33 | A multi-center randomized, double-blind, placebo controlled, parallel-group study of CD 07743 for the improvement of Lateral Canthal Lines (crow’s feet) | 2012-05-02 | due-trials |
| Reported results | 2010-022211-19 | PILOT STUDY TO EXPLORE EFFICACY AND SAFETY OF DIFFERENT DOSE REGIMENS OF CD5789 IN SUBJECTS WITH ACNE VULGARIS | 2011-06-24 | due-trials |
| Reported results | 2010-024214-54 | Exploratory study to assess facial tolerability after daily application of several concentrations and formulations containing CD5789 in acne subjects | 2011-07-25 | due-trials |
| Reported results | 2011-002057-65 | Effect of CD08100/02 3% gel versus placebo in subjects presenting with erythematotelangiectatic rosacea over a 4 week treatment period. | 2011-12-23 | due-trials |
| Reported results | 2011-002058-30 | Effect of CD08100/02 3% gel versus placebo gel in subjects presenting with papulopustular rosacea over a 6-week treatment period. | 2012-03-23 | due-trials |
| Reported results | 2011-004592-36 | Subjects? satisfaction on pan facial aesthetic enhancement after treatment with Azzalure® and the Restylane® range Satisfacción del paciente con la mejoría estética facial global después del tratam... | 2013-04-16 | due-trials |
| Reported results | 2011-004791-11 | Efficacy and safety of CD5024 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea over 16 weeks treatment, followed by a 36-week extension period | 2013-12-19 | due-trials |
| Reported results | 2012-001044-22 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY TO DEMONSTRATE THE EFFICACY AND ASSESS THE SAFETY OF CD07805/47 GEL 0.5% APPLIED TOPICALLY ONCE DAILY IN SUBJECTS WITH... | 2013-10-18 | due-trials |
| Reported results | 2012-005686-12 | Patient-Reported outcomes of Brimonidine Tartrate 0.5% gel for treatment of severe facial erythema of rosacea Patientrapporterade utfall av brimonidintartrat 0,5 % gel för behandling av svårt ansik... | 2013-11-19 | due-trials |
| Reported results | 2013-000544-26 | Determination of antifungal activity of Loceryl® Nail Lacquer 5% when used concomitantly with a cosmetic nail varnish compared to a Loceryl® Nail Lacquer 5% alone in treatment of toenail Distal Subung... | 2016-01-21 | due-trials |
| Reported results | 2013-000973-54 | Multi-centre, randomized, investigator-blind, intra-individual active and vehicle-controlled study, comparing Metvix® Natural Daylight Photodynamic Therapy versus Metvix® conventional Photodynamic The... | 2014-01-06 | due-trials |
| Completed, but no date, and reported results | 2013-001796-20 | Efficacy, safety and pharmacokinetics of 2 concentrations and 2 dosage regimens of CD5789 in subjects with Lamellar Ichthyosis | bad-data | |
| Reported results | 2013-005083-26 | Effect of CD07805/47 gel in subjects presenting with flushing related to erythematotelangiectatic or papulopustular rosacea | 2014-06-30 | due-trials |
| Reported results | 2014-000710-53 | A multicenter open label uncontrolled study of the long term safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 26 weeks in pediatric subjects (2 to 16 years and 11 months of a... | 2018-05-29 | due-trials |
| Reported results | 2014-001744-38 | A multicenter, randomized, double blind, parallel group, vehicle controlled, study of the safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 8 weeks in pediatric subjects (2 to... | 2016-01-18 | due-trials |
| Reported results | 2014-001755-23 | A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 50μg/g CREAM IN SUBJECTS WITH ACNE VULGARIS | 2017-02-23 | due-trials |
| Reported results | 2014-002509-39 | Effect of Patient Education on Treatment Adherence and Satisfaction among Acne Patients Receiving Once-Daily EpiduoTM Gel Treatment in Primary Care Clinics | 2015-08-18 | due-trials |
| Reported results | 2015-001237-24 | Subject adherence and satisfaction for treatment of Onychomycosis with Loceryl® Nail Lacquer 5% versus Ciclopoli® Nail Lacquer. Therapietreue und Zufriedenheit der Patienten bei der Behandlung von ... | 2016-08-25 | due-trials |
| Reported results | 2015-001448-13 | Benzaknen® 5% Gel in combination with Dermotivin® Soft Liquid cleanser and non-comedogenic Cetaphil® Dermacontrol Moisturizer SPF30 in the treatment of mild-to-moderate acne vulgaris | 2016-01-15 | due-trials |
| Reported results | 2015-001503-31 | Subject adherence and satisfaction for treatment of Onychomycosis with Loceryl® Nail Lacquer 5% versus Canesten® Fungal Nail Treatment Set | 2016-09-14 | due-trials |
| Reported results | 2015-002540-13 | A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50µg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris Estud... | 2017-06-12 | due-trials |
| Reported results | 2016-000063-16 | Efficacy and safety of CD5024 1% in acne vulgaris | 2016-11-02 | due-trials |
| Reported results | 2016-002860-15 | A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris | 2017-11-16 | due-trials |
| Reported results | 2016-005025-37 | A randomized, double-blind, multi-center, parallel-group, placebo-controlled dose-ranging study to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis subje... | 2018-09-21 | due-trials |
| Completed, but no date, and reported results | 2017-000066-29 | Subject reported outcomes on satisfaction, efficacy and safety with Luxerm® in the field-directed treatment of thin or non-hyperkeratotic and non-pigmented Actinic Keratosis of the face or the scalp | bad-data | |
| Reported results | 2017-000157-40 | Efficacy comparison of Ivermectin 1% topical cream associated with Doxycycline 40 mg Modified release (MR) capsules versus Ivermectin 1% topical cream associated with Placebo in the treatment of seve... | 2018-01-23 | due-trials |
| Reported results | 2017-001677-16 | A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-... | 2020-03-17 | due-trials |
| Reported results | 2017-001715-36 | A study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) | 2018-09-26 | due-trials |
| Listed as ongoing, but also has a completion date | 2019-001887-31 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis | 2022-08-11 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-001888-75 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis | 2022-09-26 | bad-data |
| Other | 2019-001889-15 | A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2019-004293-25 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis | 2023-02-21 | bad-data |
| Other | 2019-004294-13 | A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis | not-yet-due | |
| Not reported | 2019-004789-17 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis | 2022-03-30 | due-trials |
| Completed, report not yet due | 2020-000229-24 | An Open-label Drug-Drug Interaction Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Severe Atopic Dermatitis | 2023-06-07 | not-yet-due |
| Reported results | 2020-001992-34 | Clinical Trial Exit Interview Study in Cutaneous T-cell Lymphoma (CTCL) to Capture Meaningful Treatment Benefit from a Patient’s Perspective Befragungsstudie nach Behandlungsabschluss bei kutanem ... | 2021-04-16 | due-trials |
| Ongoing, reported early | 2020-006050-51 | Evaluation of the risk of atrophic acne scar formation during treatment of acne vulgaris subjects with trifarotene 50 µg/g cream versus vehicle cream over 24 weeks Évaluation du risque de formation... | not-yet-due | |
| Ongoing | 2021-000448-23 | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe A... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-002166-40 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis with Inadequate Response to or for Whom Cycl... | 2023-04-14 | bad-data |
| Reported results | 2021-003608-41 | Evaluation of acne-induced hyperpigmentation during treatment of acne vulgaris subjects with trifarotene 50 µg/g cream versus vehicle cream over 24 weeks. Evaluación de la hiperpigmentación inducid... | 2022-12-15 | due-trials |
| Listed as ongoing, but also has a completion date | 2021-003928-32 | A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects with Prurigo Nodularis | 2023-09-11 | bad-data |
| Listed as ongoing, but also has a completion date | 2021-004766-35 | A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects with Chronic Kidney Disease with Associated Moderate to Severe Pruritus | 2024-01-03 | bad-data |